Similar articles

• Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial.

  Flaker G, Lopes RD, Hylek E, Wojdyla DM, Thomas L, Al-Khatib SM, Sullivan RM, Hohnloser SH, Garcia D, Hanna M, Amerena J, Harjola VP, Dorian P, Avezum A, Keltai M, Wallentin L, Granger CB; ARISTOTLE Committees and Investigators. Flaker G, et al. J Am Coll Cardiol. 2014 Oct 14;64(15):1541-50. doi: 10.1016/j.jacc.2014.07.967. J Am Coll Cardiol. 2014. PMID: 25301455 Clinical Trial.
• Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study.

  DiMarco JP, Flaker G, Waldo AL, Corley SD, Greene HL, Safford RE, Rosenfeld LE, Mitrani G, Nemeth M; AFFIRM Investigators. DiMarco JP, et al. Am Heart J. 2005 Apr;149(4):650-6. doi: 10.1016/j.ahj.2004.11.015. Am Heart J. 2005. PMID: 15990748 Clinical Trial.
• Edoxaban vs. warfarin in patients with atrial fibrillation on amiodarone: a subgroup analysis of the ENGAGE AF-TIMI 48 trial.

  Steffel J, Giugliano RP, Braunwald E, Murphy SA, Atar D, Heidbuchel H, Camm AJ, Antman EM, Ruff CT. Steffel J, et al. Eur Heart J. 2015 Sep 1;36(33):2239-45. doi: 10.1093/eurheartj/ehv201. Epub 2015 May 13. Eur Heart J. 2015. PMID: 25971288 Clinical Trial.
• [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].

  Selçuk H, Selçuk MT, Maden O. Selçuk H, et al. Anadolu Kardiyol Derg. 2007 Mar;7(1):54-8. Anadolu Kardiyol Derg. 2007. PMID: 17347079 Review. Turkish.
• Comparing Direct Oral Anticoagulants and Warfarin for Atrial Fibrillation, Venous Thromboembolism, and Mechanical Heart Valves.

  Marcy TR, Truong T, Rai A. Marcy TR, et al. Consult Pharm. 2015 Nov;30(11):644-56. doi: 10.4140/TCP.n.2015.644. Consult Pharm. 2015. PMID: 26629800 Review.